Financial Capital

In an endeavour towards The Company generates financial capital annually in the form of surplus, arising from the current business operations, financing activities and investing activities through monetisation of assets and investments. We follow asset light model which allows us to generate rich cash and cash equivalents. Our 91.5% of the centre network and 16.1% lab network do not require capital and hence are asset light. During the year, we initiated cost rationalisation measures and have been successful in reducing fixed and semi-variable costs.

Performance Highlights

Revenue

(₹ in crores)

Ebidta

(₹ in crores)

Pat

(₹ in crores)

PAT before CSR, one-time share based and other expenses

(₹ in crores)

Cash & Cash Equivalents

(₹ in crores)

Patient

(mn)

Number of tests

(mn)

Revenue per Patient

Revenue per Test

43.9%

A growth of 100 bps B2C Sales Contribution

1.25 Crores,

Capex towards setting up Covid-19 Testing Facilities

20%

Redcuction in fixed and and semi-Variable Costs